Humacyte, Inc. (NASDAQ:HUMA) Given Average Recommendation of “Buy” by Analysts

Shares of Humacyte, Inc. (NASDAQ:HUMA) have earned an average recommendation of “Buy” from the eight analysts that are currently covering the company, Marketbeat Ratings reports. One research analyst has rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the company. The average twelve-month price objective among analysts that have issued ratings on the stock in the last year is $13.71.

HUMA has been the subject of several recent research reports. Benchmark restated a “buy” rating on shares of Humacyte in a research report on Thursday, February 27th. D. Boral Capital reissued a “buy” rating and set a $25.00 price objective on shares of Humacyte in a research report on Wednesday. Finally, HC Wainwright restated a “buy” rating and issued a $15.00 price objective on shares of Humacyte in a research note on Wednesday, March 12th.

Humacyte Trading Down 2.5 %

Shares of HUMA opened at $1.96 on Friday. The firm has a fifty day simple moving average of $3.61 and a two-hundred day simple moving average of $4.51. The firm has a market cap of $246.68 million, a PE ratio of -1.46 and a beta of 1.36. Humacyte has a 1-year low of $1.76 and a 1-year high of $9.97.

Humacyte (NASDAQ:HUMA) last posted its earnings results on Friday, March 28th. The company reported ($0.16) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.23) by $0.07. As a group, research analysts forecast that Humacyte will post -1.27 EPS for the current fiscal year.

Institutional Trading of Humacyte

A number of hedge funds and other institutional investors have recently modified their holdings of the company. Vontobel Holding Ltd. purchased a new position in shares of Humacyte during the 4th quarter valued at $50,000. Petros Family Wealth LLC purchased a new position in shares of Humacyte in the fourth quarter valued at about $50,000. Syon Capital LLC bought a new position in shares of Humacyte in the fourth quarter worth about $54,000. Brookstone Capital Management bought a new position in shares of Humacyte in the fourth quarter worth about $56,000. Finally, ACT Wealth Management LLC purchased a new stake in shares of Humacyte during the fourth quarter worth about $57,000. 44.71% of the stock is owned by hedge funds and other institutional investors.

About Humacyte

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.